Contact
If you need media that scales, we'd like to help. Get in touch with us using the form below.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
If you need media that scales, we'd like to help. Get in touch with us using the form below.
At Multus, we’re fortunate to be guided by a world-class Scientific Advisory Board - experts who help us make high-impact decisions as we build the next generation of growth media.
One of those experts is Professor Michael Butler, a pioneering voice in bioprocessing and mammalian cell technology with a career spanning four decades, three countries, and over 200 scientific contributions. Mike’s strategic and technical insights support our senior leadership and R&D teams as we scale our platform and product portfolio across biopharma.
Professor Butler is currently Principal Investigator in Cell Technology at the National Institute of Bioprocessing Research & Training (NIBRT) in Ireland and Adjunct Full Professor at University College Dublin. He previously held long-standing academic leadership positions in Canada, including Distinguished Professor of Biochemistry at the University of Manitoba.
Throughout his career, he has led research into the production of recombinant proteins, monoclonal antibodies, and viral vaccines using mammalian cell lines. He’s especially well-known for his work on bioprocess conditions that influence the structure and function of glycoproteins - an area critical to the efficacy and safety of biopharmaceuticals.
With over 200 peer-reviewed publications, seven books, and editorial roles for journals including Biotechnology and Bioengineering, Mike has shaped the global discourse on cell-based manufacturing.
Mike’s career has consistently bridged the gap between academia and industry. He is a past recipient of the Canadian Synergy Award for university-industry innovation and founder of Biogro Technologies, a serum-free media spinout.
“Multus is a young, vibrant, and energetic company that has grown impressively over the last few years. Multus is expanding a unique technology at the intersection of biology, engineering, and AI” Mike said. “The team understands the complexity of cell culture, but also the urgency of delivering practical solutions that work at scale. It’s a company I’m proud to support.”
Mike’s journey to joining Multus started in an unusually fitting way: through his own textbook chapters. While researching serum-free media, Multus co-founder Cai Linton came across Mike’s extensive body of work and recognised him as the person who literally wrote the book on the subject.
Cai reached out, hoping to connect with the author of titles like Animal Cell Culture and Technology and Mammalian Cell Biotechnology, and was met with a warm response. The relationship grew from there.
His decades of experience, captured in works published by Oxford University Press, Taylor & Francis, and others, continue to shape how modern biomanufacturers think about media innovation. Having him on board is both a privilege and a powerful asset as Multus works to redefine what’s possible in cell culture media.
Multus Co-founder and CEO Cai Linton shared, “Mike’s insights and experience will be invaluable as we grow our impact in the biomanufacturing space. His ability to translate rigorous science into commercial success is exactly what we need as we bring next-gen growth media to market.”
As biomanufacturing becomes a key strategic priority for governments and industry alike, Mike’s addition to the Advisory Board will help us to continue building credible, high-performance solutions that unlock scale across sectors.
Follow us on LinkedIn to meet more of the people shaping the future of biomanufacturing.
Sign up for email updates:
